Drug intelligence / Profile preview

flufenamic acid + heparin sodium + hydroxyethyl salicylate

Development stage
Unknown
Lead developer
Permamed
Modality
Small Molecules
Administration
Topical
01

Overview

Assan Dolo Emgel is a topical combination formulation developed and manufactured by Permamed AG for the treatment of painful and inflammatory musculoskeletal disorders, rheumatic complaints, and blunt injuries. It contains three active ingredients: flufenamic acid, a non-steroidal anti-inflammatory drug (NSAID) of the fenamate class that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis; hydroxyethyl salicylate, a salicylate derivative with analgesic and anti-inflammatory properties; and heparin sodium, an anticoagulant that improves local microcirculation and aids in the reduction of swelling. The emulsion gel (emgel) formulation is alcohol-free, non-greasy, and approved in Switzerland (Swissmedic) for over-the-counter use.

Brand names
ASSAN doloAssan Dolo EmgelAssan EmgelAssan Gel
Other names
flufenamic acid + heparin sodium + hydroxyethyl salicylateflufenaminsäure + heparin-natrium + hydroxyethylsalicylat
02

Targets

AKR1B1 (Aldose Reductase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATIII (Antithrombin III)TAS2R14 (Taste receptor type 2 member 14)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on flufenamic acid + heparin sodium + hydroxyethyl salicylate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on flufenamic acid + heparin sodium + hydroxyethyl salicylate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call